Pregnancy and commonly usage hematological medications in Sudan

Haj Elamin. E. Azhari; Abozer Y Elderdery; R. R Mohammed; H. E. Omer; A. M. Iman; Entesar M Tabein; Osama  Ramadan; Mostafa Shaban

doi:10.53730/ijhs.v6nS1.7126

Authors

Haj Elamin. E. Azhari Department of Clinical Pharmacy and Pharmacy Practice - Karary University, Khartoum University& Military Hospitals (Sudan)
Abozer Y Elderdery
ayelderdeery@ju.edu.sa
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Kingdom of Saudi Arabia and Health Sciences Research Unit, Jouf University, Sakaka, Saudi Arabia
Mohammed. R.R Omdurman Islamic University (Sudan)
H. E. Omer Fellowship of Sudan medical specialization board, Khartoum Teaching Hospital (Sudan)
A. M. Iman Omdurman Islamic University (Sudan)
Entesar M Tabein College of Applied Medical Sciences, Shagra University, Saudi Arabia
Osama Ramadan Department of Nursing, College of Applied medical Sciences, Jouf University, Sakaka, Saudi Arabia
Mostafa Shaban Department of Nursing, College of Applied medical Sciences, Jouf University, Sakaka, Saudi Arabia

Keywords:

Pregnant women, Medications, Hematological Drugs, Trimester, Folic Acid, Ferrous Sulphate

Abstract

Background: When a woman with hematological issues considers pregnancy, she may need to take drugs. Objectives: This research looked into the use of hematological drugs to treat illnesses like anemia. Methods: This is a descriptive retrospective cross-sectional hospital-based study which carried out in Military Hospitals and Khartoum Teaching Hospital (Sudan) from Jan 2014 - Jan 2015. Data collection form was used to extract the information from 650 pregnant patient files. The information recorded included: age, trimester, medical history and hematological drugs. Results and Discussion: Four hundred & forty two (N=442=68%) of the women had normal (75-90%) hemoglobin, and 208 (32%) were below normal (40-70%) hemoglobin. Four hundred & thirty one (66.3%) of the pregnant women were dispensed hematological medications and the consumption was significantly higher in the third trimester (7-9 months) 89.6% of women (N = 386) than the second trimester (4-6 months) 10% of women (N = 43) and the first trimester (1-3 months) 0.46% of women (N = 2).

Downloads

Download data is not yet available.

References

A. M. Bolla et al., “Awareness about diabetes and pregnancy among diabetes specialists and fellows: The YoSID diabetes and pregnancy project,” Nutr. Metab. Cardiovasc. Dis., vol. 30, no. 9, pp. 1520–1524, Aug. 2020, doi: 10.1016/j.numecd.2020.04.019.

I. Bancos et al., “Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature,” Lancet Diabetes Endocrinol., vol. 9, no. 1, pp. 13–21, Jan. 2021, doi: 10.1016/S2213-8587(20)30363-6.

R. Ryu and M. F. Hebert, “Impact of pregnancy on maternal pharmacokinetics of medications,” in Clinical Pharmacology During Pregnancy, Elsevier, 2022, pp. 19–46.

M. M. Shaban, N. M. Abdou, and A. I. A. Rehim, “Occupational Asthma Severity among Flour Mill Workers and Adherence to Preventive Guidelines,” Indian J. Public Heal. Res. Dev., vol. 10, no. 10, p. 1245, 2019, doi: 10.5958/0976-5506.2019.03002.X.

K. M. Adams Waldorf and R. M. McAdams, “Influence of infection during pregnancy on fetal development,” REPRODUCTION, vol. 146, no. 5, pp. R151–R162, Nov. 2013, doi: 10.1530/REP-13-0232.

Y. Fukushima, Y. Yamamoto, E. Yamazaki, K. Imai, Y. Kagawa, and Y. Takahashi, “Change in the pharmacokinetics of lacosamide before, during, and after pregnancy,” Seizure, vol. 88, pp. 12–14, May 2021, doi: 10.1016/j.seizure.2021.03.011.

M. Codaccioni and C. Brochot, “Assessing the impacts on fetal dosimetry of the modelling of the placental transfers of xenobiotics in a pregnancy physiologically based pharmacokinetic model,” Toxicol. Appl. Pharmacol., vol. 409, p. 115318, Dec. 2020, doi: 10.1016/j.taap.2020.115318.

T. Takaku, H. Nagahori, and Y. Sogame, “Metabolism and physiologically based pharmacokinetic modeling of flumioxazin in pregnant animals,” Toxicol. Appl. Pharmacol., vol. 277, no. 3, pp. 242–249, Jun. 2014, doi: 10.1016/j.taap.2014.03.022.

C. Oh, E. Keats, and Z. Bhutta, “Vitamin and Mineral Supplementation During Pregnancy on Maternal, Birth, Child Health and Development Outcomes in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis,” Nutrients, vol. 12, no. 2, p. 491, Feb. 2020, doi: 10.3390/nu12020491.

D. Churchill, M. Nair, S. J. Stanworth, and M. Knight, “The change in haemoglobin concentration between the first and third trimesters of pregnancy: a population study,” BMC Pregnancy Childbirth, vol. 19, no. 1, p. 359, Dec. 2019, doi: 10.1186/s12884-019-2495-0.

I. L. Kron et al., “Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation,” J. Thorac. Cardiovasc. Surg., 2015, doi: 10.1016/j.jtcvs.2014.10.120.

H. H. Mohammed, N. A. El-gawad, and S. H. Mohammady, “ASSESSMENT OF MATERNAL AND NEW-BORN COMPLICATIONS FOLLOWING UNPLANNED CESAREAN,” J. Cardiovasc. Dis. Res., vol. 12, no. 03, pp. 2985–2994, 2021, doi: 10.31838/jcdr.2021.12.03.387.

D. E. Fuster Guillen, “Investigación cualitativa: Método fenomenológico hermenéutico,” Propósitos y Represent., vol. 7, no. 1, p. 201, Jan. 2019, doi: 10.20511/pyr2019.v7n1.267.

P. Sachdeva, B. Patel, and B. Patel, “Drug use in pregnancy; a point to ponder!,” Indian J. Pharm. Sci., vol. 71, no. 1, p. 1, 2009, doi: 10.4103/0250-474X.51941.

J. V. Ilekis et al., “Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development,” Am. J. Obstet. Gynecol., vol. 215, no. 1, pp. S1–S46, Jul. 2016, doi: 10.1016/j.ajog.2016.03.001.

A. Kammala et al., “Fetal Membranes Contribute to Drug Transport across the Feto-Maternal Interface Utilizing the Breast Cancer Resistance Protein (BCRP),” Life, vol. 12, no. 2, p. 166, Jan. 2022, doi: 10.3390/life12020166.

S. W. Gloria Connolly, “Gerontological Nursing Competencies and Standards of Practice 2010,” Can. Gerontol. Nurs. Assoc., no. Vancouver, p. 4, 2010.

S. Maghsoudlou et al., “Maternal haemoglobin concentrations before and during pregnancy and stillbirth risk: a population-based case-control study,” BMC Pregnancy Childbirth, vol. 16, no. 1, p. 135, Dec. 2016, doi: 10.1186/s12884-016-0924-x.

A. Al-Naseem, A. Sallam, S. Choudhury, and J. Thachil, “Iron deficiency without anaemia: a diagnosis that matters,” Clin. Med. (Northfield. Il)., vol. 21, no. 2, pp. 107–113, Mar. 2021, doi: 10.7861/clinmed.2020-0582.

C. H. Villa, D. C. Pan, S. Zaitsev, D. B. Cines, D. L. Siegel, and V. R. Muzykantov, “Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier,” Ther. Deliv., vol. 6, no. 7, pp. 795–826, Jul. 2015, doi: 10.4155/tde.15.34.

K. Grzeszczak, S. Kwiatkowski, and D. Kosik-Bogacka, “The Role of Fe, Zn, and Cu in Pregnancy,” Biomolecules, vol. 10, no. 8, p. 1176, Aug. 2020, doi: 10.3390/biom10081176.

M. Danhof, “Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models,” J. Pharmacokinet. Pharmacodyn., vol. 42, no. 5, pp. 447–462, Oct. 2015, doi: 10.1007/s10928-015-9437-x.